February 1, 2022

February 2022 Anthem Provider News - Nevada

Contents

AdministrativeCommercialFebruary 1, 2022

Heart disease is the number one killer of women

AdministrativeCommercialFebruary 1, 2022

It is CAHPS survey time!

Medical Policy & Clinical GuidelinesCommercialFebruary 1, 2022

Medical Policy and clinical UM guidelines notification (MAC)

Products & ProgramsCommercialFebruary 1, 2022

Cancer Care Navigator

PharmacyCommercialFebruary 1, 2022

February 2022 specialty pharmacy updates (MAC)

PharmacyCommercialFebruary 1, 2022

Pharmacy information available on anthem.com

State & FederalMedicare AdvantageFebruary 1, 2022

Get faster payments with EFT

State & FederalMedicaidFebruary 1, 2022

Keep up with Medicaid news

State & FederalMedicaidFebruary 1, 2022

Get faster payments with EFT

State & FederalMedicare AdvantageFebruary 1, 2022

Keep up with Medicare news

AdministrativeCommercialFebruary 1, 2022

Anthem will no longer accept medical attachments through VYNE Medical effective May 1, 2022 (MAC)

Material adverse change (MAC)

 

Anthem Blue Cross and Blue Shield (Anthem) entered into a pilot program to accept electronic medical attachment from VYNE Medical. This pilot program expired and the grace period for submitting electronic attachments through VYNE Medical has expired.


On May 1, 2022, attachments submitted through VYNE Medical will no longer be accessible by Anthem.  Thus, you may not submit attachments for claims you are submitting to Anthem through VYNE.
The alternative for submitting medical attachments is through Electronic Data Interchange (EDI) or through Availity.com. This will ensure your medical attachments re appropriately received and aligned to the correct claim.

 

If you are not enrolled in Availity.com and EDI, the process is simple. Log onto Availity.com/provider-portal-registration to go through the step-by-step process for enrollment. For information about how to enroll in EDI, use this convenient Batch EDI Standard Companion Guide after logging onto Availity.com.

 

For more information about enrolling in Availity, contact their client services department at

800-282-4548, Monday through Friday, 8:00 a.m. to 8:00 p.m. ET.

 

314-0222-PN-NV

AdministrativeCommercialFebruary 1, 2022

Prepare for the Consolidated Appropriations Act: Keep your provider directory information current

The Consolidated Appropriations Act (CAA) effective January 1, 2022, contains a provision that requires online provider directory information be reviewed and updated (if needed) at least every 90 days. We are asking you to review your online provider directory information to help ensure Anthem Blue Cross and Blue Shield (Anthem) members can locate the most current information for in-network providers and facilities.

 

You can help us ensure your online provider directory information is current by:

 

  • Reviewing your online provider directory information on a regular basis to ensure it is correct. You can check your directory listing on Anthem’s Find Care Consumers, members, brokers, and providers use the Find Care tool to identify in-network physicians and other healthcare providers supporting member health plans. To ensure we have your most current and accurate information, please take a moment to access Find Care. Go to anthem.com/provider, then under Provider Overview, choose Find Care.

 

  • Submitting updates and corrections to your directory information by using our online Provider Maintenance Form. Online update options include:
    • add/change an address location
    • name change
    • tax ID changes
    • provider leaving a group or a single location
    • phone/fax number changes
    • closing a practice location

 

Once you submit the Provider Maintenance Form, you will receive an email acknowledging receipt of your request. Visit the Provider Maintenance Form landing page for complete instructions.

 

1538-0222-PN-NV

AdministrativeCommercialFebruary 1, 2022

Heart disease is the number one killer of women



National Wear Red Day is a great way to keep heart aware. It is also a great opportunity to have a conversation with your patients about their heart health. The Centers for Disease Control and Prevention (CDC) has information you can share with your patients, including a helpful Know the Facts about Heart Disease flyer that’s free for health care professionals.

 

Controlling high blood pressure, diabetes, extra weight, and unhealthy diets are heart disease contributors that you can help your patients recognize. For information about these heart disease risks to share with your patients, use the CDC website for toolkits, flyers, and give-a-ways.

 

Measure Up: Controlling High Blood Pressure (CBP)

Known as the “silent killer,” high blood pressure or hypertension increases the risk of heart disease.

 

The HEDIS® measure CBP looks at the percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (140/90) in the measurement year. Record all blood pressure readings and the dates they were taken being sure to record the exact reading. Blood pressure readings captured during telehealth, virtual care, telephone, or e-visit should also be recorded.

 

Measure Up: Statin Therapy for Patients with Cardiovascular Disease and Diabetes (SPC/SPD)

Statins are effective at lowering cholesterol and protecting against heart attack and stroke. Patients with diabetes also have elevated cardiovascular risk.

  • Statin therapy for patients with cardiovascular disease (STC). HEDIS measure assesses males 21-75 years of age and females 40-75 years of age who have clinical atherosclerotic cardiovascular disease and who received and adhered to statin therapy.
  • Statin therapy for patients with diabetes (STD) assesses adults 40-75 years of age who have diabetes and who do not have clinical ASCVD, who received and adhered to statin therapy.

 

Adherence to prescribed medication is key to patient care and SPC/SPD measure success.

 

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

1535-0222-PN-NV

ATTACHMENTS (available on web): Image 1535.jpg (jpg - 0.06mb)

AdministrativeCommercialFebruary 1, 2022

It is CAHPS survey time!

The Consumer Assessment of Healthcare Providers and Systems (CAHPS) is an annual standardized survey conducted starting February 2022 through May2022 to assess consumers’ experience with their provider and health plan. A random sample of your adult or child patients may get the survey. Over half of the questions used for scoring are directly impacted by providers. These questions are:
  • When you needed care right way, how often did you get care as soon as you needed?
  • How often did you get an appointment for a check-up or routine care as soon as you needed?
  • How often was it easy to get the care, tests, or treatment you needed?
  • How often did you get an appointment to see a specialist as soon as you needed?
  • How often did your personal doctor seem informed and up-to-date about the care you got from other doctors or other health providers?
  • How would you rate your personal doctor?
  • How would you rate the specialist you see most often?
  • How would you rate all your health care in the last 6 months?


Interested in how you can improve CAHPS performance? Anthem offers an online course for providers and office staff designed to learn how to improve communication skills, build patient trust and commitment, and expand your knowledge of the CAHPS survey. The Improving the Patient Experience course is available at no cost and is eligible for one CME credit by the American Academy of Family Physicians. It can be accessed at mydiversepatients.com/le-ptexp.html.


1514-0221-PN-NV

Medical Policy & Clinical GuidelinesCommercialFebruary 1, 2022

Medical Policy and clinical UM guidelines notification (MAC)

Material adverse change (MAC)

 

Anthem Blue Cross and Blue Shield and our subsidiary company, HMO Nevada (collectively “Anthem”) are pleased to provide you with our updated and new medical policies. Anthem will also be implementing changes to the clinical utilization management (UM) guidelines adopted by Nevada.

 

Summarized below are the major new policies and changes. Refer to the specific policy for coding, language, and rationale updates and changes not summarized below.

 

New medical policies effective for service dates on and after May 1, 2022:

  • 00044 Wheelchair Mounted Robotic Arm Attachment: This document addresses the use of a wheelchair mounted robotic arm attachment intended for use in individuals with upper extremity disability, to create a sense of independence with mobility restraints and gain autonomy due to neurologic conditions, trauma, or other problems.
    • Considered Investigational and Not Medically Necessary
    • Prior authorization required effective May 1, 2022

 

  • 000138 Wearable Devices for Stress Relief and Management: Wearable devices for stress relief are typically small and inconspicuous sensors worn on the wrist, waist, skin, or clothes to aid wearers in identifying stressful triggers. Stress relief wearables often include biofeedback to help wearers learn to modify their physiologic response and may contain a therapeutic intervention, such as a calming vibration, activated by device-detected physiologic stressful stimuli.
    • Considered investigational and not medically necessary in all situations.
    • Prior authorization required effective May 1, 2022

 

 

Revised Medical Policies and Adopted Clinical UM Guidelines effective May 1, 2022:

  • CG-MED-53 Cervical Cancer Screening Using Cytology and Human Papillomavirus Testing: This document addresses cervical cancer screening and testing for human papillomavirus (HPV) to assess cervical cancer risk. Currently cervical cancer screening comprises cervical cytology with Papanicolaou testing (also known as a ‘Pap test’), and testing for HPV DNA. Pap tests are used to identify pre-cancerous or cancerous tissues present on the cervix.  Screen for HPV aids in identifying individuals at higher risk for developing cervical cancer.  
    • Removed criteria addressing chronically immunosuppressed individuals.

 

  • CG-SURG-78 Locoregional and Surgical Techniques for Treatment Primary and Metastatic Liver Malignancies: This document addresses surgical excision and locoregional therapies to treat primary or metastatic cancer of the liver. Treatment focuses on excising tumors or inducing tumor necrosis and can be used as a curative or palliative therapy, as a bridge to liver transplantation, or in those who may become eligible for liver transplantation with treatment. Local regional therapies may include any of the following ablative and arterially directed therapies:
    • Ablative Therapy
      • Cryosurgical ablation or cryotherapy
      • Microwave ablation (MWA)
      • Percutaneous ethanol injection (PEI)
      • Radiofrequency ablation (RFA)
    • Arterially directed therapy
      • Immunoemobolization
      • Selective internal radiation therapy (SIRT); also known as transarterial radioembolization (TARE)
      • Transcatheter arterial chemoembolization (TACE)
      • Transcatheter arterial embolization (TAE)
    • Revised the clinical indications to add a NMN statement for histotripsy

 

  • 00099 Navigational Bronchoscopy: This document addresses the use of navigational bronchoscopy (NB) devices as an aid in accessing peripheral lung lesions and masses, which may be inaccessible by standard bronchoscopy. ENB has also been proposed as a means of placing fiducial markers for surgical and radiological procedures.
    • Revised title
    • Removed the word “electromagnetic” in the position statement.

 

  • 00010 Treatments for Urinary Incontinence: This document addresses the following for urinary incontinence:
    • Vaginal weight training;
    • Injection of periurethral bulking agents;
    • Transvaginal radiofrequency bladder neck suspension;
    • Transurethral radiofrequency energy collagen micro-remodeling;
    • Artificial urinary sphincter devices;
    • Intraurethral valve-pump implantation;
    • Adjustable balloon system implantation.
      • Added new criterion to INV&NMN statement on endovaginal cryogen-cooled, monopolar radiofrequency remodeling.
      • Added “as treatment for urinary incontinence” to INV&NMN statement and removed wording on urinary incontinence.

 

  • 00097 Scoliosis Surgery: This document addresses vertebral body stapling and vertebral body tethering as surgical treatments of scoliosis.
    • Revised title.
    • Added “minimally invasive deformity correction system” to the scope and position statement.

 

Medical policies to require prior authorization effective May 1, 2022:

DME.00032 Automated External Defibrillators for Home Use

LAB.00011 Analysis of Proteomic Patterns

MED.00002 Selected Sleep Testing Services

MED.00090 Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders

MED.00099 Navigational Bronchoscopy

MED.00115 Outpatient Cardiac Hemodynamic Monitoring Using a Wireless Sensor for Heart Failure Management

OR-PR.00005 Upper Extremity Myoelectric Orthoses

OR-PR.00006 Powered Robotic Lower Body Exoskeleton Devices

RAD.00053 Cervical and Thoracic Discography

SURG.00011 Allogeneic, Xenographic, Synthetic and Composite Products for Wound Healing and Soft Tissue Grafting

SURG.00062 Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele

SURG.00071 Percutaneous and Endoscopic Spinal Surgery

SURG.00088 Coblation® Therapies for Musculoskeletal Conditions

SURG.00107 Prostate Saturation Biopsy

SURG.00119 Endobronchial Valve Devices

SURG.00126 Irreversible Electroporation

SURG.00131 Lower Esophageal Sphincter Augmentation Devices for the Treatment of Gastroesophageal Reflux Disease

SURG.00132 Drug-Eluting Devices for Maintaining Sinus Ostial Patency

SURG.00140 Peripheral Nerve Blocks for Treatment of Neuropathic Pain

SURG.00141 Doppler-Guided Transanal Hemorrhoidal Dearterialization

SURG.00142 Genicular Nerve Blocks and Ablation for Chronic Knee Pain

SURG.00143 Perirectal Spacers for Use During Prostate Radiotherapy

SURG.00150 Leadless Pacemaker

SURG.00151 Balloon Dilation of Eustachian Tube

TRANS.00004 Cell Transplantation (Mesencephalic, Adrenal-Brain and Fetal Xenograft)

TRANS.00008 Liver Transplantation

TRANS.00009 Lung and Lobar Transplantation

TRANS.00010 Autologous and Allogeneic Pancreatic Islet Cell Transplantation

TRANS.00011 Pancreas Transplantation and Pancreas Kidney Transplantation

TRANS.00013 Small Bowel, Small Bowel/Liver and Multivisceral Transplantation

TRANS.00016 Umbilical Cord Blood Progenitor Cell Collection, Storage and Transplantation

TRANS.00023 Hematopoietic Stem Cell Transplantation for Multiple Myeloma and Other Plasma Cell Dyscrasias

TRANS.00024 Hematopoietic Stem Cell Transplantation for Select Leukemias and Myelodysplastic Syndrome

TRANS.00026 Heart/Lung Transplantation

TRANS.00027 Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors

TRANS.00028 Hematopoietic Stem Cell Transplantation for Hodgkin Disease and non-Hodgkin Lymphoma

TRANS.00029 Hematopoietic Stem Cell Transplantation for Genetic Diseases and Aplastic Anemias

TRANS.00030 Hematopoietic Stem Cell Transplantation for Germ Cell Tumors

TRANS.00031 Hematopoietic Stem Cell Transplantation for Autoimmune Disease and Miscellaneous Solid Tumors

TRANS.00033 Heart Transplantation

TRANS.00034 Hematopoietic Stem Cell Transplantation for Diabetes Mellitus

TRANS.00035 Other Adult Stem Cell Therapy

 

Medical policies and clinical guidelines archived November 18, 2021 (except where noted)

  • 00095 Anterior Segment Optical Coherence Tomography
  • 00126 Fractional Exhaled Nitric Oxide and Exhaled Breath Condensate Measurements for Respiratory Disorders
  • OR-PR.00004 Partial-Hand Myoelectric Prosthesis
    • Content moved to CG-OR-PR-05

 

Medical policies and clinical guidelines archived December 29, 2021 (except where noted)

  • CG-BEH-01 Assessment of Autism Spectrum Disorders and Rett Syndrome Medical
  • CG-MED-32 Ancillary Services for Pregnancy Complications
  • CG-MED-77 SPECT/CT Fusion Imaging
  • CG-MED-87 Single Photon Emission Computed Tomography Scans for Noncardiovascular Indications
  • 00036 Genetic Testing for Hereditary Pancreatitis
    • Content moved to CG-GENE-13
  • 00047 Methyenetetrahydrofolate Reductase Mutation Testing
    • Content moved to CG-GENE-13
  • 00117 Autologous Cell Therapy for the Treatment of Damaged Myocardium
    • Content moved to TRANS.00035

 

Clinical Guidelines de-adopted January 1, 2022

  • CG-DME-33 Wheeled Mobility Devices: Manual Wheelchairs-Ultra Lightweight
  • CG-DME-34 Wheeled Mobility Devices: Wheelchair Accessories
  • CG-DME-40 Noninvasive Electrical Bone Growth Stimulation of the Appendicular Skeleton
  • CG-MED-70 Wireless Capsule Endoscopy for Gastrointestinal Imaging and the Patency Capsule
  • CG-SURG-30 Tonsillectomy for Children With or Without Adenoidectomy
  • CG-SURG-72 Endothelial Keratoplasty
  • CG-SURG-77 Refractive Surgery
  • CG-SURG-87 Nasal Surgery for the Treatment of Obstructive Sleep Apnea and Snoring
  • CG-THER-RAD-07 Intravascular Brachytherapy (Coronary and Non-Coronary)

 

Anthem medical policies and clinical UM guidelines are developed by our national Medical Policy and Technology Assessment Committee. The committee, which includes Anthem medical directors and representatives from practicing physician groups, meets quarterly to review current scientific data and clinical developments.

 

All coverage written or administered by Anthem excludes from coverage, services or supplies that are investigational and/or not medically necessary. A member’s claim may not be eligible for payment if it was determined not to meet medical necessity criteria set in Anthem’s medical policies. Review procedures have been refined to facilitate claim investigation.

 

Anthem’s medical policies and clinical UM guidelines are available on the Policies and Guidelines page under the Provider Resources heading on our anthem.com/provider website. From there, enter key word or code, or select the link for Full List page to search the policy for your inquiry. 

 

To view the list of specific clinical UM guidelines adopted by Nevada, navigate to the View Medical Policies & UM Guidelines page. Scroll to the bottom of the page to the link titled Clinical UM Guidelines adopted by Anthem Blue Cross and Blue Shield in Nevada.

 

1522-0222-PN-NV

Products & ProgramsCommercialFebruary 1, 2022

Cancer Care Navigator

The Cancer Care Navigator (CCN) program is a comprehensive cancer support solution for oncologists and Anthem Blue Cross and Blue Shield (Anthem) members who are at high risk for complications during treatment. This program is aimed at helping to simplify the complexities of cancer care for members.

 

Providers are given a single point of contact to connect the practice to the right people at Anthem to help lessen administrative burdens. CCN also gives the practice access to Anthem’s advanced predictive analytics to help identify patients at high risk for complications, in turn allowing providers the opportunity to take preventive action and guide targeted interventions.

Patients are provided with a wealth of support through supplemental services (dietitians, pharmacists, etc.), medication adherence assistance, individualized care plans, and goal setting, as well as after-hours telephonic and digital support.

CCN is the ultimate support service to improve the care experience and quality of life to allow patients time to focus on overall health and well-being. Please feel free to reach out to the CCN team at 1-833-649-0669.

 

1515-0222-PN-NV

PharmacyCommercialFebruary 1, 2022

February 2022 specialty pharmacy updates (MAC)

Material adverse change (MAC)

 

Specialty pharmacy updates for Anthem Blue Cross and Blue Shield (Anthem) are listed below.

 

Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by Anthem’s medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by AIM Specialty Health® (AIM), a separate company.

 

Please note, inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code.

 

Prior authorization updates

Effective for dates of service on and after May 1, 2022, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.

 

Access our Clinical Criteria to view the complete information for these prior authorization updates.

 

Clinical Criteria

Drug

HCPCS or CPT Code(s)

*ING-CC-0204

Tivdak

J3490, J3590, J9999

ING-CC-0072

Byooviz

J3590

ING-CC-0068

Skytrofa

J3490

* Oncology use is managed by AIM.

 

Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity.

 

Step therapy updates

Effective for dates of service on and after May 1, 2022, the following specialty pharmacy codes from current clinical criteria documents will be included in our existing specialty pharmacy medical step therapy review process. 

 

Access our Clinical Criteria to view the complete information for these step therapy updates.

 

Clinical Criteria

Status

Drug

HCPCS or CPT Code(s)

ING-CC-0072

Non-Preferred

Byooviz

J3590

 

Quantity limit updates

Effective for dates of service on and after May 1, 2022, the following specialty pharmacy codes from current clinical criteria documents will be included in our quantity limit review process.

 

Access our Clinical Criteria to view the complete information for these quantity limit updates.

 

Clinical Criteria

Drug

HCPCS or CPT Code(s)

ING-CC-0072

Byooviz

J3590

 

1526-0222-PN-NV

PharmacyCommercialFebruary 1, 2022

Pharmacy information available on anthem.com

Visit the Drug Lists page on anthem.com for more information on:
  • Copayment/coinsurance requirements and their applicable drug classes
  • Drug lists and changes
  • Prior authorization criteria
  • Procedures for generic substitution
  • Therapeutic interchange
  • Step therapy or other management methods subject to prescribing decisions
  • Any other requirements, restrictions, or limitations that apply to using certain drugs

 

The commercial drug list is posted to the website quarterly on the first day of the month in January, April, July, and October.

 

FEP Pharmacy updates and other pharmacy related information may be accessed at fepblue.org > Pharmacy Benefits.

 

1532-0222-PN-NV

State & FederalMedicare AdvantageFebruary 1, 2022

Get faster payments with EFT

Medicare Advantage

 

Effective November 1, 2021, EnrollSafe* at enrollsafe.payeehub.org replaced
Enrollhub® from the Council for Affordable Quality Healthcare, Inc. (CAQH) as the electronic funds transfer (EFT) enrollment website at no cost to Anthem Blue Cross and Blue Shield providers.

 

EnrollSafe is safe, secure, and available 24-hours a day

Log onto the EnrollSafe enrollment hub at enrollsafe.payeehub.org to enroll in EFT. You will be directed through the EnrollSafe secure website to the Registration page, where you will provide the required information to create an account and then Enroll to supply your banking information.

 

Already enrolled in EFT through CAQH Enrollhub?

If you were previously enrolled in EFT through CAQH Enrollhub, no action is needed unless you are making changes. Your EFT enrollment information will not change as a result of the new enrollment hub.

 

If you have changes to make, use enrollsafe.payeehub.org to update your account.

 

 

*EnrollSafe is a tool developed by Zelis Payments, an independent organization offering electronic fund transfer services on behalf of Anthem Blue Cross and Blue Shield.

 

ABSCRNU-0287-21

State & FederalMedicaidFebruary 1, 2022

Updates to the Anthem Blue Cross and Blue Shield Healthcare Solutions provider manual for Nevada Medicaid

Medicaid

 

We have made some recent changes to the Anthem Blue Cross and Blue Shield Healthcare Solutions provider manual for Nevada Medicaid.

 

Our updated provider manual is available for use and distribution as of January 1, 2022. You can obtain a copy by visiting the following website: providers.anthem.com/nv.

 

If you have any questions regarding these changes, please contact your Provider Experience associate at 844-396-2330.

 

ANV-NU-0299-21

State & FederalMedicaidFebruary 1, 2022

Reducing the burden of medical record review and improving health outcomes with HEDIS ECDS reporting

Medicaid

 

This communication applies to Medicaid under Anthem Blue Cross and Blue Shield Healthcare Solutions and Medicare Advantage under Anthem Blue Cross and Blue Shield (Anthem).

 

The HEDIS® Electronic Clinical Data Systems (ECDS) reporting methodology encourages the exchange of the information needed to provide high-quality healthcare services. 

 

The ECDS Reporting Standard provides a method to collect and report structured electronic clinical data for HEDIS quality measurement and improvement. 

 

Benefits to providers:

  • Reduced burden of medical record review for quality reporting
  • Improved health outcomes and care quality due to greater insights for more specific patient-centered care

 

ECDS reporting is part of the National Committee for Quality Assurance’s (NCQA) larger strategy to enable a Digital Quality System and is aligned with the industry’s move to digital measures. 

 

Learn more about NCQA’s digital quality system and what it means to you and your practice at the following link: ncqa.org/hedis/the-future-of-hedis/hedis-electronic-clinical-data-system-ecds-reporting/.

 

ECDS measures

The first publicly reported measure using the HEDIS ECDS Reporting Standard is the Prenatal Immunization Status (PRS) measure. In 2022, NCQA will include the PRS measure in Health Plan Ratings for Medicaid and Commercial plans for measurement year 2021.

 

For HEDIS measurement year 2022, the following measures can be reported using ECDS: 

  • Childhood Immunization Status (CIS-E)*
  • Immunizations for Adolescents (IMA-E)*
  • Breast Cancer Screening (BCS-E)
  • Colorectal Cancer Screening (COL-E)
  • Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)
  • Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)*
  • Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)
  • Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)
  • Depression Remission or Response for Adolescents and Adults (DRR-E)
  • Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)
  • Adult Immunization Status (AIS-E)
  • Prenatal Immunization Status (PRS-E) (Accreditation measure for 2021)
  • Prenatal Depression Screening and Follow-Up (PND-E)
  • Postpartum Depression Screening and Follow-Up (PDS-E)

 

* Indicates that this is the first year that the measure can be reported using ECDS.

Of note, NCQA added the ECDS reporting method to three existing HEDIS measures: Breast Cancer Screening, Colorectal Cancer Screening, and Follow-Up Care for Children Prescribed ADHD Medication. Initially, the ECDS method will be optional, which provides health plans an opportunity to try out reporting using the ECDS method before it is required to transition to ECDS only in the future.

 

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

 

ANV-NU-0289-21

State & FederalMedicaidFebruary 1, 2022

Get faster payments with EFT

Medicaid

 

This communication applies to Medicaid under Anthem Blue Cross and Blue Shield Healthcare Solutions and Medicare Advantage under Anthem Blue Cross and Blue Shield (Anthem).

 

Effective November 1, 2021, EnrollSafe* at enrollsafe.payeehub.org replaced Enrollhub® from the Council for Affordable Quality Healthcare, Inc. (CAQH) as the electronic funds transfer (EFT) enrollment website at no cost to Anthem providers.

 

EnrollSafe is safe, secure, and available 24-hours a day

Log onto the EnrollSafe enrollment hub at enrollsafe.payeehub.org to enroll in EFT. You will be directed through the EnrollSafe secure website to the Registration page, where you will provide the required information to create an account and then Enroll to supply your banking information.

 

Already enrolled in EFT through CAQH Enrollhub?

If you were previously enrolled in EFT through CAQH Enrollhub, no action is needed unless you are making changes. Your EFT enrollment information will not change as a result of the new enrollment hub.

 

If you have changes to make, use enrollsafe.payeehub.org to update your account.

 

*EnrollSafe is a tool developed by Zelis Payments, an independent organization offering electronic fund transfer services on behalf of Anthem.


ANV-NU-0288-21

State & FederalMedicaidFebruary 1, 2022

Botox update for Anthem Blue Cross and Blue Shield Healthcare Solutions members

Medicaid


Please note:

  • This is not a change in member benefits. This is a change in the Botox vendor only.
  • If the member is not using CVS* Specialty Pharmacy or IngenioRx* Specialty Pharmacy to obtain Botox, no action is needed.

 

For Botox managed under a member’s medical benefit

Effective January 1, 2022, you will need to buy this drug and bill Anthem Blue Cross and Blue Shield Healthcare Solutions.

 

If you have questions regarding a member’s medical specialty pharmacy benefits, call Provider Services at 844-396-2330.

 

For Botox managed under a member’s pharmacy benefit

Effective January 1, 2022, members who currently obtain Botox through IngenioRx Specialty Pharmacy using their pharmacy benefit must change to another in-network pharmacy that distributes Botox.

 

If you have questions regarding a member’s pharmacy benefit, call Pharmacy Member Services at 833-207-3116.

 

* CVS is an independent company providing pharmacy services on behalf of Anthem Blue Cross and Blue Shield Healthcare Solutions. IngenioRx, Inc. is an independent company providing pharmacy benefit management services on behalf of Anthem Blue Cross and Blue Shield Healthcare Solutions.


ANV-NU-0287-21

State & FederalMedicaidFebruary 1, 2022

The Behavioral Health Areas of Expertise Profile improves the referral process

Medicaid

The Behavioral Health Areas of Expertise Profile (BHAEP) is designed to highlight your behavioral health network providers’ services, cultural preferences, race, languages spoken, and other specialties to our members through the enhancement of our online provider directory. The goal is to help our members find the right behavioral health provider to fit their unique needs. 

 

Contracted Medicaid providers are asked to answer a brief online survey on their clinical areas of expertise, demographics, modalities, and accessibility. The data collected provides insight into our behavioral health providers’ capabilities, which assists in member referral, provider network strategy development, and proposal support. Completion of the BHAEP does not affect a provider’s credentialing materials/status or contract.

 

By capturing this information, we are able to:

  • Improve identification of specific services and/or specialties.
  • Improve the referral process by better identifying provider capabilities.
  • Align with competitors that provide this data in their online provider directories.

 

Currently, the BHAEP is administered in 18 Medicaid markets. The local health plan completes provider outreach. While data gathered through this tool has proven to be helpful to members, providers, and the health plan, response rates remain low.

 

View your State’s BHAEP survey here.

 

ANV-NU-0285-21

State & FederalMedicare AdvantageFebruary 1, 2022

Reducing the burden of medical record review and improving health outcomes with HEDIS ECDS reporting

Medicare Advantage

 

This communication applies to Medicaid under Anthem Blue Cross and Blue Shield Healthcare Solutions and Medicare Advantage under Anthem Blue Cross and Blue Shield (Anthem).

 

The HEDIS® Electronic Clinical Data Systems (ECDS) reporting methodology encourages the exchange of the information needed to provide high-quality healthcare services. 

 

The ECDS Reporting Standard provides a method to collect and report structured electronic clinical data for HEDIS quality measurement and improvement. 

 

Benefits to providers:

  • Reduced burden of medical record review for quality reporting
  • Improved health outcomes and care quality due to greater insights for more specific patient-centered care

 

ECDS reporting is part of the National Committee for Quality Assurance’s (NCQA) larger strategy to enable a Digital Quality System and is aligned with the industry’s move to digital measures. 

 

Learn more about NCQA’s digital quality system and what it means to you and your practice at the following link: ncqa.org/hedis/the-future-of-hedis/hedis-electronic-clinical-data-system-ecds-reporting/.

 

ECDS measures

The first publicly reported measure using the HEDIS ECDS Reporting Standard is the Prenatal Immunization Status (PRS) measure. In 2022, NCQA will include the PRS measure in Health Plan Ratings for Medicaid and Commercial plans for measurement year 2021.

 

For HEDIS measurement year 2022, the following measures can be reported using ECDS: 

  • Childhood Immunization Status (CIS-E)*
  • Immunizations for Adolescents (IMA-E)*
  • Breast Cancer Screening (BCS-E)
  • Colorectal Cancer Screening (COL-E)
  • Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)
  • Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)*
  • Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)
  • Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)
  • Depression Remission or Response for Adolescents and Adults (DRR-E)
  • Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)
  • Adult Immunization Status (AIS-E)
  • Prenatal Immunization Status (PRS-E) (Accreditation measure for 2021)
  • Prenatal Depression Screening and Follow-Up (PND-E)
  • Postpartum Depression Screening and Follow-Up (PDS-E)

 

* Indicates that this is the first year that the measure can be reported using ECDS.

Of note, NCQA added the ECDS reporting method to three existing HEDIS measures: Breast Cancer Screening, Colorectal Cancer Screening, and Follow-Up Care for Children Prescribed ADHD Medication. Initially, the ECDS method will be optional, which provides health plans an opportunity to try out reporting using the ECDS method before it is required to transition to ECDS only in the future.

 

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

 

ANV-NU-0289-21